Celldex Therapeutics, Inc.

NasdaqCM:CLDX Stock Report

Market Cap: US$1.2b

Celldex Therapeutics Valuation

Is CLDX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CLDX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$10.39
Fair Value
94.3% overvalued intrinsic discount
12
Number of Analysts

Below Fair Value: CLDX ($20.18) is trading above our estimate of fair value ($10.39)

Significantly Below Fair Value: CLDX is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLDX?

Key metric: As CLDX barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CLDX. This is calculated by dividing CLDX's market cap by their current book value.
What is CLDX's PB Ratio?
PB Ratio1.9x
BookUS$702.98m
Market CapUS$1.22b

Price to Book Ratio vs Peers

How does CLDX's PB Ratio compare to its peers?

The above table shows the PB ratio for CLDX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.1x
GRAL GRAIL
0.5x28.28%US$1.2b
AGIO Agios Pharmaceuticals
1.2x-23.07%US$1.6b
AUPH Aurinia Pharmaceuticals
2.9x15.94%US$1.1b
IMCR Immunocore Holdings
3.9x49.27%US$1.4b
CLDX Celldex Therapeutics
1.9x26.49%US$1.2b

Price-To-Book vs Peers: CLDX is good value based on its Price-To-Book Ratio (1.9x) compared to the peer average (2.1x).

Price to Book Ratio vs Industry

How does CLDX's PB Ratio compare vs other companies in the US Biotechs Industry?

82 CompaniesPrice / BookEstimated GrowthMarket Cap
FDMT 4D Molecular Therapeutics
0.3x-5.80%US$142.68m
NKTX Nkarta
0.4x-2.33%US$136.95m
FATE Fate Therapeutics
0.4x-5.46%US$119.19m
LYEL Lyell Immunopharma
0.3x5.46%US$118.14m
CLDX 1.9xIndustry Avg. 1.5xNo. of Companies83PB01.63.24.86.48+
82 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CLDX is expensive based on its Price-To-Book Ratio (1.9x) compared to the US Biotechs industry average (1.4x).

Price to Book Ratio vs Fair Ratio

What is CLDX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLDX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CLDX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CLDX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$20.18
US$57.25
+183.70%
28.76%US$90.00US$31.00n/a12
May ’26US$20.71
US$62.23
+200.49%
25.10%US$90.00US$36.00n/a13
Apr ’26US$16.85
US$62.08
+268.45%
26.18%US$90.00US$36.00n/a12
Mar ’26US$20.57
US$63.55
+208.92%
25.49%US$90.00US$36.00n/a11
Feb ’26US$24.49
US$67.10
+173.99%
21.66%US$90.00US$42.00n/a10
Jan ’26US$25.27
US$67.10
+165.53%
21.66%US$90.00US$42.00n/a10
Dec ’25US$27.44
US$67.10
+144.53%
21.66%US$90.00US$42.00n/a10
Nov ’25US$25.68
US$67.40
+162.46%
20.83%US$90.00US$44.00n/a10
Oct ’25US$32.40
US$67.11
+107.13%
22.01%US$90.00US$44.00n/a9
Sep ’25US$41.33
US$67.00
+62.11%
22.83%US$90.00US$37.00n/a9
Aug ’25US$37.55
US$66.78
+77.84%
23.57%US$90.00US$35.00n/a9
Jul ’25US$38.99
US$66.78
+71.27%
23.57%US$90.00US$35.00n/a9
Jun ’25US$33.30
US$70.29
+111.07%
22.93%US$90.00US$35.00n/a7
May ’25US$39.35
US$70.71
+79.71%
22.97%US$90.00US$35.00US$20.717
Apr ’25US$41.64
US$70.71
+69.82%
22.97%US$90.00US$35.00US$16.857
Mar ’25US$51.88
US$69.43
+33.83%
24.25%US$90.00US$35.00US$20.577
Feb ’25US$35.50
US$63.29
+78.27%
25.47%US$80.00US$27.00US$24.497
Jan ’25US$39.66
US$63.29
+59.57%
25.47%US$80.00US$27.00US$25.277
Dec ’24US$32.02
US$63.29
+97.64%
25.47%US$80.00US$27.00US$27.447
Nov ’24US$23.57
US$59.57
+152.74%
28.19%US$73.00US$21.00US$25.687
Oct ’24US$27.52
US$59.57
+116.47%
28.19%US$73.00US$21.00US$32.407
Sep ’24US$28.81
US$59.57
+106.77%
28.19%US$73.00US$21.00US$41.337
Aug ’24US$34.76
US$65.60
+88.72%
10.41%US$73.00US$54.00US$37.555
Jul ’24US$33.93
US$66.33
+95.50%
9.72%US$73.00US$54.00US$38.996
Jun ’24US$32.13
US$66.33
+106.45%
9.72%US$73.00US$54.00US$33.306
May ’24US$31.35
US$66.50
+112.12%
9.22%US$73.00US$55.00US$39.356
AnalystConsensusTarget
Consensus Narrative from 12 Analysts
US$57.25
Fair Value
64.8% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/12 14:14
End of Day Share Price 2025/05/12 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Celldex Therapeutics, Inc. is covered by 22 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan AschoffBrean Capital
Edward NashCanaccord Genuity
Kristen KluskaCantor Fitzgerald & Co.